Tuesday, September 1, 2026

8:00 AM - 8:45 AM

---

Details

Moderators: Chairs to be confirmed Programme: Overview MOTU-0201 - Collaborative pharmacist medication prescribing: An Australian experience Pharmacist prescribing has been implemented in many jurisdictions around the world, with countries like Canada and the UK leading the way in this expanded scope of practice for pharmacists. Australia has recently implemented collaborative pharmacist medication prescribing in many hospitals across the country. As digital health is still evolving, few hospitals with fully electronic health records have adopted collaborative pharmacist medication prescribing to date. In addition, few studies have explored stakeholder perspectives and the best way to implement an effective collaborative pharmacist medication prescribing service, particularly in a digital health environment. In this session, we will describe experiences and outcomes following the introduction of collaborative pharmacist medication prescribing in eight urban and rural digital hospitals in Australia. We will provide an overview of collaborative pharmacist medication prescribing in the Australian hospital setting including pharmacist scope of practice, training and credentialing of prescribers and system requirements to enable pharmacist prescribing in a digital healthcare setting. We will report on patient and health system outcomes of collaborative pharmacist medication prescribing, drawing from insights gained through conducting a major, randomised, multi-site research programme across South Australia and Queensland. All collaborative pharmacist medication prescribing in this programme is linked to electronic health records, offering insights into the benefits of an electronic, rather than paper-based, healthcare setting. Patient, physician, and pharmacist perspectives on the implementation of collaborative pharmacist medication prescribing and its impact on patient reported outcome and experience measures will be discussed. Lessons learned from the introduction in a variety of medical and surgical settings will be presented. We will contrast the Australian experience with international experience, delivering a presentation that is relevant for anyone who is interested in pharmacist prescribing around the world. MOTU-0202 – Belgian community pharmacists: guardians of quality primary health care High-quality work is embedded in the DNA of Belgian community pharmacists. For many years, under the leadership of the sector’s representative body, Association of Pharmacists Belgium (APB), a strategy has been developed to enhance visibility, measurability and verifiability. Programmes were set up to monitor the quality of both licensed and compounded medicines on the Belgian market, as well as the quality of dispensed pharmaceutical care through self-evaluation and simulated patients. Since 2024, the introduction of external professional audits has added an additional dimension. To make all this possible, APB has, over the last decades, invested heavily in Laboratory expertise and powerful online tools. APB’s Medicines Control Laboratory (est. 1952) has recently obtained a GMP label, is responsible for both routine and highly specialised analyses of medicines, conducts research into the formulation of specific compounded preparations, and is also responsible for recalling batches when a quality issue is identified. Belgian community pharmacists typically use APB’s online quality tools on a daily basis, for instance to manage the pharmacy’s quality manual, perform self-inspections, or participate in the quality programmes mentioned above. Moreover, checking the Shared Pharmaceutical Record or uploading a Shared Medication Plan, as part of day-to-day pharmaceutical care, is only possible thanks to APB’s reliable digital services. More recent technology such as e-Forms allow for real-time documentation and registration of advanced services, including vaccination and medication reviews. Looking ahead, future investment in the development and routine use of quality indicators related to pharmacy operations will allow for improved quality assurance. This also means greater focus can be placed on improving the quality of primary data and investigating how emerging technologies such as artificial intelligence can contribute to the high-quality provision of medicines, products, healthcare services and health data.

---

Chairs & speakers